BHC

Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Retrieved on: 
Monday, August 15, 2022 - 12:05pm

The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.

Key Points: 
  • The dosing of the first patient in this exploratory trial marks an important milestone for Virios, as we develop new combination antiviral therapies to improve care standards for patients suffering from virally mediated diseases, said Greg Duncan, Chairman and Chief Executive Officer of Virios Therapeutics.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • Evidence of IMC-1s efficacy on a broad spectrum of FM outcome measures was previously demonstrated in a Phase 2a clinical trial.
  • BHC is a non-profit, interdisciplinary Center of Excellence advancing the diagnosis and treatment of chronic fatigue disorders, FM, post-viral syndromes, and related comorbidities.

Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 11, 2022 - 12:05pm

Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.

Key Points: 
  • Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases including fibromyalgia , today announced financial results for the second quarter ended June 30, 2022.
  • Research and development expenses for the second quarter ended June 30, 2022 were $2.4 million, compared to $3.2 million for the second quarter ended June 30, 2021.
  • General and administrative expenses for the second quarter ended June 30, 2022 were $1.3 million, compared to $1.1 million for the second quarter ended June 30, 2021.
  • Virios Therapeutics management will host a webcast and conference call on August 11, 2022, at 8:30 a.m.

Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Retrieved on: 
Wednesday, August 10, 2022 - 11:00pm

As previously stated, the Company will appeal this decision to the U.S. Court of Appeals for the Federal Circuit and it expects an appeal decision to issue within 12 to 18 months.

Key Points: 
  • As previously stated, the Company will appeal this decision to the U.S. Court of Appeals for the Federal Circuit and it expects an appeal decision to issue within 12 to 18 months.
  • To date, Norwich has not received tentative or final approval of its ANDA from the FDA.
  • Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products.
  • With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference

Retrieved on: 
Wednesday, August 10, 2022 - 9:01pm

ET

Key Points: 
  • ET
    The conference is completely complementary to qualified investors.
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).
  • The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
  • The Q3 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors.

It's Bigger Than Us Partners With Baldwin Hills Crenshaw To Host Its 3RD Annual Back 2 School Event

Retrieved on: 
Saturday, August 6, 2022 - 4:00am

LOS ANGELES,  Aug. 5, 2022 /PRNewswire-PRWeb/ -- Non-profit Organization, It's Bigger Than Us 501c(3) (IBTU), will host its 3rd Annual Back 2 School event on Saturday, Aug. 6th, 2022, at the Baldwin Hills Crenshaw shopping center (3650 W Martin Luther King Jr Blvd, Los Angeles, CA 90008) with a volunteer start at 9 a.m.; event celebrations begin at 1 p.m. This event will provide students from South Los Angeles with 5,000 backpacks, school supplies, family-friendly activities, and resources to improve the health and well-being of families.

Key Points: 
  • I'm excited that we will partner with the legendary Baldwin Hills Crenshaw shopping center this year.
  • All of my childhood was spent hanging out at Baldwin Hills Crenshaw shopping, eating, and going to the movie theater with friends and family to now be able to host IBTU's 3rd Annual Back 2 School event here is a dream."
  • Volunteers will assemble 1,750 elementary school backpacks, 1,500 middle school backpacks, and 1,750 high school backpacks.
  • About Baldwin Hills Crenshaw Plaza Baldwin Hills Crenshaw (BHC) is an 870,000-square-foot retail destination located at the intersection of Crenshaw Blvd.

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022

Retrieved on: 
Thursday, August 4, 2022 - 12:05pm

Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m.

Key Points: 
  • Management will also host a webcast and conference call on August 11, 2022 at 8:30 a.m.
  • ET to discuss the results and provide a corporate update.
  • The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and Presentations .
  • Virios Therapeutics (Nasdaq: VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, such as fibromyalgia (FM).

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

Retrieved on: 
Thursday, July 28, 2022 - 8:45pm

LAVAL, Quebec, July 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC), and its gastroenterology business Salix Pharmaceuticals, today announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. regarding the infringement and validity of certain U.S. Patents protecting the composition and use of XIFAXAN® (rifaximin) 550 mg tablets for the treatment of irritable bowel syndrome with diarrhea (IBS-D) and reduction in risk of overt hepatic encephalopathy (HE) recurrence.

Key Points: 
  • When the Court enters a final order, Bausch Health will consider all available options to vigorously defend the intellectual property protecting XIFAXAN and will appeal the Court's decision to the U.S. Court of Appeals for the Federal Circuit.
  • We strongly disagree with any conclusion that our patents are not valid and intend to file an appeal to any such order," Thomas J. Appio, CEO, Bausch Health, said.
  • The Company intends to file an appeal immediately after any final order is issued, assuming it is consistent with the Oral Order.
  • Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products.

Bausch Health Companies Inc. Will Release Second-Quarter 2022 Financial Results on Aug. 9

Retrieved on: 
Thursday, July 28, 2022 - 12:35am

9325022 (replay available until Aug. 16, 2022)

Key Points: 
  • 9325022 (replay available until Aug. 16, 2022)
    Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products.
  • We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health, through our approximately 90% ownership of Bausch + Lomb Corporation.
  • With our leading durable brands, we are delivering on our commitments as we build an innovative company dedicated to advancing global health.
  • For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn .

Bausch + Lomb Provides Leadership Update

Retrieved on: 
Wednesday, July 20, 2022 - 12:00pm

"Joe has done an incredible job as the former leader of Bausch Health and current leader of Bausch + Lomb.

Key Points: 
  • "Joe has done an incredible job as the former leader of Bausch Health and current leader of Bausch + Lomb.
  • After six years as CEO, and after accomplishing the IPO of Bausch + Lomb, I believe now is an appropriate time to transition leadership of the Company.
  • Bausch + Lomb, with the support of its Board, remains committedto the strategy of completing its spinoff from Bausch Health.
  • "On behalf of the entire Board of Bausch + Lomb, I thank Joe for his leadership, commitment to the Company and focus on its people and patients," said John Paulson, a member of the Board and chair of the Board of Directors of Bausch Health.

Salix Announces 2022 Gastrointestinal Health Scholars Program Winners

Retrieved on: 
Wednesday, July 13, 2022 - 12:00pm

LAVAL, QC, July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, today announced the winners of its 2022 Salix Gastrointestinal Health Scholars Program. For the third consecutive year, Salix will be awarding $10,000 each to 10 students living with a GI disease.

Key Points: 
  • LAVAL, QC, July 13, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) and liver diseases and disorders, todayannounced the winners of its 2022 Salix Gastrointestinal Health Scholars Program.
  • "Salix is pleased to recognize these 10 outstanding Salix Gastrointestinal Health Scholarship awardees who are thriving in their academic journey while living with the challenges of a gastrointestinal condition," said Nicola Kayel, vice president, Marketing, Salix.
  • The 2022 Salix Gastrointestinal Health Scholars Program recipients are:
    "It's hard to express my gratitude and how grateful I truly am for this opportunity," said Joshua Swimmer, a recipient of the Working Parent's Award and a student at the University of Southern Indiana.
  • To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.salix.com/scholarship .